Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zimberelimab (GLS-010) is a humanized monoclonal antibody targeting PD-1, with antitumor activity. It blocks the interaction between PD-L1, PD-L2, and PD-1 on the cell surface, and is used in studies of cervical cancer and non-small cell lung cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,530 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Zimberelimab (GLS-010) is a humanized monoclonal antibody targeting PD-1, with antitumor activity. It blocks the interaction between PD-L1, PD-L2, and PD-1 on the cell surface, and is used in studies of cervical cancer and non-small cell lung cancer. |
Targets&IC50 | PD-1 (human):210 pM (EC50) |
In vitro | Zimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab can effectively block the binding of PD-L1 and PD-L2 to PD-1 on the cell surface in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. [1] The equilibrium dissociation constant (KD) between Zimberelimab and PD-1 is 1.75×10-10 M. [2] |
In vivo | Zimberelimab showed a statistically significant antitumor effect in the MC38 model of human PD-1 knock-in mice. [2] |
Alias | WBP-3055, WBP3055, GLS-010, GLS010, AB-122, AB122 |
Cas No. | 2259860-24-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.